Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1997–2004. doi: 10.1128/aac.36.9.1997

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

M Kinzig 1, F Sörgel 1, B Brismar 1, C E Nord 1
PMCID: PMC192425  PMID: 1329637

Abstract

The pharmacokinetics of tazobactam and piperacillin in plasma and different tissues after a 30-min intravenous infusion of 4 g of piperacillin and 0.5 g of tazobactam were investigated in 18 patients who underwent elective colorectal surgery. Serial blood samples were collected for up to 6 h after the initiation of the infusion. The types of tissue collected were fatty tissue, muscle, skin, appendix, and intestinal mucosa (proximal and distal). On the basis of concentrations in plasma, the following pharmacokinetic parameter values were obtained (values are means +/- standard deviations): maximum concentration of drug in serum, tazobactam, 27.9 +/- 7.67 micrograms/ml; piperacillin, 259 +/- 81.8 micrograms/ml; time to maximum concentration of drug in serum, tazobactam, 0.51 +/- 0.03 h; piperacillin, 0.51 +/- 0.03 h; area under the concentration-time curve, tazobactam, 47.6 +/- 13.3 micrograms.h/ml; piperacillin, 361 +/- 80.3 micrograms.h/ml; clearance, tazobactam, 188 +/- 52.3 ml/min; piperacillin, 194 +/- 42.9 ml/min; half-life, tazobactam, 1.42 +/- 0.32 h; piperacillin, 1.27 +/- 0.24 h; apparent volume of distribution, tazobactam, 0.31 +/- 0.07 liter/kg of body weight; piperacillin, 0.29 +/- 0.06 liter/kg; volume of distribution at steady state, tazobactam, 0.28 +/- 0.04 liter/kg; piperacillin, 0.25 +/- 0.05 liter/kg. The concentrations of tazobactam and piperacillin in fatty tissue and muscle tissue were 10 to 13 and 18 to 30% of the levels in plasma, respectively. In skin, the concentrations of piperacillin were 60 to 95% of the levels in plasma, whereas the concentrations of tazobactam in plasma were 49 to 93% of the levels in skin tissue. The mean concentration of tazobactam in the investigated gastrointestinal tissues (appendix, proximal and distal mucosa) exceeded levels in plasma after 1 h, while piperacillin showed a mean penetration into these tissues of 43 and 53%. The mechanisms that can be used to explain the extent of penetration of piperacillin and tazobactam are discussed. Simple diffusion may take place in fatty and muscle tissue, while penetration into skin and gastrointestinal tissue is governed by more complex mechanisms which lead to differences in penetration between piperacillin and tazobactam. For all tissues investigated (except fatty tissue), the time course of the concentrations of both compounds was similar, with a peak in concentration at between 1 and 2 h after the start of infusion followed by a decline of concentrations that were almost parallel to the curves of the drug concentrations in plasma. In plasma and in all investigated tissues, piperacillin as well as tazobactam reached or exceeded the concentrations found to be effective in vitro.

Full text

PDF
1997

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cheung W. K., Greene D. S., Kuye O., Smith M. P., Holder A., Fernandez P., Houston A., Faulkner R. D., Silber B. M. Pharmacokinetics of YTR830H in healthy human subjects. J Chemother. 1989 Jul;1(4 Suppl):505–506. [PubMed] [Google Scholar]
  2. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  3. Cullmann W., Stieglitz M. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. Chemotherapy. 1990;36(5):356–364. doi: 10.1159/000238788. [DOI] [PubMed] [Google Scholar]
  4. Diver J. M., Thornber D., Wise R. Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid. J Antimicrob Chemother. 1989 Jul;24(1):89–92. doi: 10.1093/jac/24.1.89. [DOI] [PubMed] [Google Scholar]
  5. Drusano G. L. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl. 1990;74:235–248. [PubMed] [Google Scholar]
  6. Holmes B., Richards D. M., Brogden R. N., Heel R. C. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1984 Nov;28(5):375–425. doi: 10.2165/00003495-198428050-00002. [DOI] [PubMed] [Google Scholar]
  7. Jones R. N., Barry A. L. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):495–510. doi: 10.1016/0732-8893(89)90084-9. [DOI] [PubMed] [Google Scholar]
  8. Kees F., Naber K. G., Bartoschik-Wich B., Stockmann P., Meyer G. P., Grobecker H. High-performance liquid chromatography analysis of mezlocillin, piperacillin, their degradation products, and of ioxitalamic acid in plasma and urine of healthy volunteers. Arzneimittelforschung. 1985;35(7):1099–1104. [PubMed] [Google Scholar]
  9. Kuck N. A., Jacobus N. V., Petersen P. J., Weiss W. J., Testa R. T. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969. doi: 10.1128/aac.33.11.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Schentag J. J. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis Suppl. 1990;74:218–234. [PubMed] [Google Scholar]
  11. Sörgel F., Naber K. G., Jaehde U., Reiter A., Seelmann R., Sigl G. Gastrointestinal secretion of ciprofloxacin. Evaluation of the charcoal model for investigations in healthy volunteers. Am J Med. 1989 Nov 30;87(5A):62S–65S. doi: 10.1016/0002-9343(89)90025-9. [DOI] [PubMed] [Google Scholar]
  12. Tartaglione T. A., Nye L., Vishniavsky N., Poynor W., Polk R. E. Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers. Clin Pharm. 1986 Nov;5(11):911–916. [PubMed] [Google Scholar]
  13. Tjandramaga T. B., Mullie A., Verbesselt R., De Schepper P. J., Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother. 1978 Dec;14(6):829–837. doi: 10.1128/aac.14.6.829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Welling P. G., Craig W. A., Bundtzen R. W., Kwok F. W., Gerber A. U., Madsen P. O. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob Agents Chemother. 1983 Jun;23(6):881–887. doi: 10.1128/aac.23.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES